What are chances for domestic biosimilars to succeed in global market?
Foreign expansion of Korean competitive biomedicines is going to be active.
The leading biosimilar companies are Celltrion and Samsung Bioepis. The two companies gave notices of the launch of the autoimmune treatment, ‘Remicade,’ to the European and U.S. markets, the largest biosimilar markets.
...Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
